newsfilter
← Latest News
GlobeNewswire·

Instil Bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Cash runway expected to extend from 2024 into 2025 upon completion of anticipated sale-leaseback of Tarzana, CA manufacturing site DELTA-1 trial of ITIL-168 in advanced melanoma with registrational intent anticipated to complete enrollment in 1H 2023